Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...

Bicycle's bicyclic peptide drug discovery platform is designed to produce drug candidates that have targeting properties like antibodies but are much smaller molecules, making manufacturing and ...

A 2009 study reported the design, construction and selection of a phage-encoded bicyclic peptide library that used a chemical linker for cyclization. This and other advanced display technologies ...

In a recent study published in the Journal of the American Chemical Society, researchers present the second-generation NTB bicyclic stereodiversified peptide library. Study: MYC-Targeting ...

More information: Zhonghan Li et al, MYC-Targeting Inhibitors Generated from a Stereodiversified Bicyclic Peptide Library, Journal of the American Chemical Society (2024). DOI: 10.1021/jacs.

Bicycle Therapeutics has developed a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, and will gain funding for phase 1 and phase 1b clinical trial ...

BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of data ...

BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ®) technology, today announced that management will ...

BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of ...

A 2009 study reported the design, construction and selection of a phage-encoded bicyclic peptide library that used a chemical linker for cyclization. This and other advanced display technologies ...